Data lineage, audit-readiness, and verified context — from clinical trials to regulatory submissions.
Life sciences runs on data. Clinical trial data. Real-world evidence (RWE). Safety signals pulled from thousands of sources at once. The AI tools built on top of that data can find patterns no human team could. They can shorten drug discovery timelines by months, flag adverse event signals earlier, and process regulatory submission volumes that would otherwise require far larger review teams.
The problem is provenance. When AI produces an output — a safety signal, a biomarker correlation, a proposed label claim — the first question any regulator asks is: where did this come from? Most AI systems have no answer. They produce conclusions without receipts.
That gap is why 64% of healthcare and life sciences organizations delayed AI projects in 2025 (HIMSS, 2025). Model quality isn’t the barrier. Defending the output is.
What “Trusted AI” Actually Means in a Regulated Context
In life sciences, trusted AI is a set of specific technical properties that regulators, IRBs, and auditors can verify:
Data provenance. Where did the data that produced this output come from? Which version? When was it last validated? Who authorized it?
Data lineage. How did data move through the pipeline, from source through transformation to AI input and output? What changed along the way, and when?
Chain of custody. Who touched the data, at which point? Is the record immutable?
Audit-ready output. Can a specific AI decision be pulled from a log and explained to a regulatory inspector on demand?
If any one of those four properties is missing, the AI output is undefendable in a regulatory context. Not just insufficient. Undefendable. FDA’s emerging AI/ML guidance, ICH E6(R3) for good clinical practice, and the EU AI Act all converge on the same expectation: traceability is a minimum requirement, not a best practice.
The Four Use Cases Where Data Lineage is Non-negotiable
Clinical Trials
Modern trials aggregate data from sites across multiple geographies, CROs, EDC systems, labs, and wearables. AI tools summarize that data, flag anomalies, and generate signals. FDA guidance increasingly makes this explicit: every AI-assisted finding must link back to verified, timestamped, access-controlled source data.
Without a lineage layer, a clinical operations team can usually tell you what a model concluded. They rarely can tell you which exact version of a dataset produced that conclusion, or whether that dataset was modified before the model ran.
Mithra’s Single Source of Truth® (SSOT®) registry gives every data source feeding a trial’s AI pipeline a blockchain-backed, immutable record. Every model input is tokenized at ingestion. Every output carries a receipt.
Drug Discovery and Biomarker Analysis
AI in drug discovery processes genomic datasets, literature corpora, compound libraries, and real-world patient cohorts simultaneously. The speed matters. But speed without lineage produces findings that peer reviewers and regulatory bodies cannot validate.
When a biomarker association is flagged as significant, the question isn’t only “is it real?” It’s “can you reproduce it, from the same data, using the same pipeline, and show your work?” Reproducibility depends on lineage. Lineage requires a system built for it.
Real-World Evidence (RWE)
RWE is one of the fastest-growing inputs to label expansion and post-market surveillance. It is also one of the most contested. Payers, regulators, and advisory committees challenge RWE submissions on data quality, source provenance, and selection bias. AI-generated RWE analyses add another layer of scrutiny: was the model validated? On what data? With what guardrails?
Mithra applies context monitoring and data lineage to RWE pipelines so every claim in a submission traces back to a specific, verified data source, not a general reference to “claims data” or “EHR aggregates.”
Regulatory Submissions
The FDA’s 2021 action plan for AI/ML-based software as a medical device introduced the concept of a “predetermined change control plan” — a documented, auditable process for managing AI model updates. The EU AI Act requires high-risk AI systems (which includes most clinical decision support) to maintain technical documentation, logging, and human oversight records.
Both frameworks require the same thing: a continuously maintained, auditable record of what the AI did, on what data, and with what authorization. Audit-readiness is the output of a correctly built data layer, not a reporting feature.
What the Absence of Lineage Costs
Organizations lose approximately 6% of annual revenue on average to AI making decisions on inaccurate or low-quality data (Fivetran / Vanson Bourne, 2024). In life sciences, the stakes extend further. A compromised signal in a clinical trial, an unsupported label claim, or a missed safety event can trigger regulatory action, trial suspension, or product liability exposure.
Building lineage into an AI pipeline costs a fraction of defending a decision that has none.
How Mithra Works in a Life Sciences Context
Mithra is not a replacement for the AI tools a life sciences organization already uses. It works alongside any LLM or analytics platform (OpenAI, Claude, Gemini, Copilot, proprietary models) as the trust layer underneath.
Three components do the work:
- SSOT® creates a blockchain-backed registry of authorized data sources. Every source is tokenized, timestamped, and version-controlled. When an AI queries data, it queries the SSOT registry, not a raw, ungoverned lake.
- Applies evidence verification, guardrails, and trust scoring to every AI-generated output. When a model produces a finding, Mithra validates it against the SSOT registry in real time, assigns a trust score, and attaches the lineage trail before the output reaches a decision-maker.
- Extends digital rights management (DRM) controls across the enterprise data surface: documents, datasets, and outputs. Access is logged, permissions are enforced, and every file carries a traceable chain of custody even after sharing with a CRO or regulatory agency.
Frequently Asked Questions
What regulations require AI data lineage in life sciences?
FDA’s AI/ML action plan and emerging guidance on AI in drug development, ICH E6(R3) for good clinical practice, the EU AI Act (high-risk AI classification applies to most clinical decision support), and HIPAA for any AI touching protected health information. Each framework requires the same thing: verifiable, documented, auditable AI decision trails.
Does Mithra replace our existing AI or analytics platform?
No. Mithra is LLM-agnostic and designed as a trust layer that works on top of existing AI infrastructure. If your clinical team uses a specific analytics platform or LLM, Mithra connects to it via API and applies lineage, verification, and governance without requiring a platform swap.
What is the difference between data lineage and traceability in a clinical context?
Traceability is the property of a single output: can this specific finding be traced back to its source data? Lineage is the system-wide record that makes traceability possible at scale — a continuously maintained, real-time map of where data came from, how it transformed, and which AI outputs consumed it. Traceability is what an auditor checks; lineage is what makes the check possible.
How does Mithra handle multi-site trial data from CROs and external partners?
The SSOT registry tokenizes and tracks data from external sources the same way it handles internal data. Every source gets a cryptographic identity at ingestion. When a CRO submits data, it enters the lineage chain, timestamped, access-controlled, and version-tracked, so the sponsoring organization can show exactly what external data fed any given AI output.
Can Mithra support FDA audit requests and regulatory submissions directly?
Mithra generates immutable audit logs that can be exported for regulatory inspection, aligned to FDA’s audit trail guidance and EU AI Act technical documentation requirements. The output is regulator-grade evidence, not a dashboard summary.